Clinical Trials Directory

Trials / Sponsors / Clarity Pharmaceuticals Ltd

Clarity Pharmaceuticals Ltd

Industry · 11 registered clinical trials — 3 currently recruiting.

StatusTrialPhaseStarted
Recruiting64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of
Prostate Cancer, Prostate Cancer Patients With Detectable PSA Following Prostatectomy, Prostate Cancer Recurrent
Phase 32025-05-16
RecruitingPositron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Ra
Prostate Cancer, Prostatic Neoplasms
Phase 32023-12-21
Terminated64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Ex
Prostatic Neoplasms, Castration-Resistant
Phase 1 / Phase 22023-06-15
Completed64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)
Biochemical Recurrence of Malignant Neoplasm of Prostate
Phase 22022-09-19
Completed64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)
Biochemical Recurrence of Malignant Neoplasm of Prostate
Phase 1 / Phase 22022-04-11
Recruiting64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate
Prostatic Neoplasms, Castration-Resistant
Phase 1 / Phase 22021-08-11
CompletedPositron Emission Tomography (PET) Imaging of Participants With Confirmed Prostate Cancer Using 64Cu-SAR-bisPS
Prostatic Neoplasms
Phase 12021-07-13
CompletedA Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors
Neuroendocrine Tumors
Phase 22021-03-02
Terminated67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapse
Neuroblastoma, Relapsed Neuroblastoma, Refractory Neuroblastoma
Phase 1 / Phase 22020-08-18
CompletedPeptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™
Meningioma
Phase 1 / Phase 22018-07-09
CompletedAn Imaging Study of 64Cu-SARTATE Using Positron Emission Tomography in Patients With Neuroendocrine Tumours
Neuroendocrine Tumors
EARLY_Phase 12015-05-21